Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Revcovi (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immunity deficiency (ADA-SCID) in pediatric and adult patients.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Biochemical Markers: All four patients in the study achieved undetectable levels of deoxyadenosine nucleotide (dAXP), and sufficient enzyme activity was maintained across all patients, as evidenced by trough serum ADA activity levels.
• Immune System Markers: The study reported increases in T and B cell numbers for all patients, along with slightly elevated and maintained IgM and IgA immunoglobulin levels.
• Comparison to Other Drugs: Elapegademase demonstrated comparable efficacy to pegademase in enzyme-replacement therapy for ADA deficiency, with no significant differences in effectiveness among different population types or subgroups.
• Serious adverse events occurred in three patients, but these events were assessed as unrelated to elapegademase.
• One infant patient died of pneumonia caused by cytomegalovirus infection, which was not attributed to elapegademase. No drug-related adverse events or significant safety concerns were reported.